Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 5, 2026, 4:54 AM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1201–1224 of 2,084 matching trials from the live ClinicalTrials.gov search.

Filters: Intervention: Open Label Extension Study Clear all

Conditions: Cervical Dystonia
Interventions: Botulinum toxin type A; Biological
Lead sponsor: Ipsen; Industry
Eligibility: 18 Years and older
Enrollment: 108 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2006 – 2008
U.S. locations: 14
States / cities: Phoenix, Arizona • Fountain Valley, California • Los Angeles, California + 10 more

Conditions: Acquired Immunodeficiency Syndrome, HIV Infections
Interventions: E/C/F/TDF, E/C/F/TAF Placebo, E/C/F/TAF, E/C/F/TDF Placebo; Drug
Lead sponsor: Gilead Sciences; Industry
Eligibility: 18 Years and older
Enrollment: 279 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2011 – 2016
U.S. locations: 40
States / cities: Birmingham, Alabama • Phoenix, Arizona • Beverly Hills, California + 30 more

Conditions: Exudative Age-related Macular Degeneration
Interventions: RBM-007; Drug
Lead sponsor: Ribomic USA Inc; Industry
Eligibility: 55 Years and older
Enrollment: 40 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2021
U.S. locations: 6
States / cities: Phoenix, Arizona • Sacramento, California • Walnut Creek, California + 3 more

Conditions: Alzheimer's Disease
Interventions: Lecanemab 2.5 mg/kg, Lecanemab 5.0 mg/kg, Lecanemab 10 mg/kg, Placebo; Drug
Lead sponsor: Eisai Inc.; Industry
Eligibility: 50 Years to 90 Years
Enrollment: 856 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2012 – 2024
U.S. locations: 91
States / cities: Birmingham, Alabama • Phoenix, Arizona • Tucson, Arizona + 70 more

Conditions: Fabry Disease
Interventions: pegunigalsidase alfa; Drug
Lead sponsor: Chiesi Farmaceutici S.p.A.; Industry
Eligibility: 18 Years and older
Enrollment: 29 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2026
U.S. locations: 7
States / cities: Birmingham, Alabama • Atlanta, Georgia • Iowa City, Iowa + 4 more

Conditions: Hyperoxaluria, Primary
Interventions: Oxabact OC5 - Oxalobacter formigenes Strain HC-1; Biological
Lead sponsor: OxThera; Industry
Eligibility: 3 Years and older
Enrollment: 22 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2021
U.S. locations: 1
States / cities: Nashville, Tennessee

Conditions: Chronic Inflammatory Demyelinating Polyneuropathy (CIDP), Polyradiculoneuropathy, Chronic Inflammatory Demyelinating
Interventions: IgPro20; Biological
Lead sponsor: CSL Behring; Industry
Eligibility: 18 Years and older
Enrollment: 82 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2017
U.S. locations: 5
States / cities: Birmingham, Alabama • Los Angeles, California • Kansas City, Kansas + 2 more

Conditions: Hereditary Angioedema (HAE)
Interventions: Deucrictibant; Drug
Lead sponsor: Pharvaris Netherlands B.V.; Industry
Eligibility: 12 Years and older
Enrollment: 170 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2028
U.S. locations: 13
States / cities: Birmingham, Alabama • Scottsdale, Arizona • Little Rock, Arkansas + 10 more

Conditions: Bipolar I Disorder, Manic or Mixed
Interventions: divalproex sodium; Drug
Lead sponsor: Abbott; Industry
Eligibility: 10 Years to 17 Years
Enrollment: 150 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: Started 2004
U.S. locations: 1
States / cities: North Chicago, Illinois

Conditions: Healthy
Interventions: ALO-02 (Oxycodone Naltrexone); Drug
Lead sponsor: Pfizer; Industry
Eligibility: 18 Years to 55 Years
Enrollment: 24 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2011 – 2012
U.S. locations: 1
States / cities: New Haven, Connecticut

Conditions: Crohn's Disease
Interventions: Filgotinib, Placebo; Drug
Lead sponsor: Lakefront Biotherapeutics NV; Industry
Eligibility: 18 Years and older
Enrollment: 1,188 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2023
U.S. locations: 100
States / cities: Dothan, Alabama • Sun City, Arizona • Coronado, California + 80 more

Conditions: Healthy Participants
Interventions: Lorcaserin manufactured at Zofingen, Lorcaserin manufactured at Kawashima; Drug
Lead sponsor: Eisai Inc.; Industry
Eligibility: 18 Years to 55 Years
Enrollment: 40 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2018
U.S. locations: 1
States / cities: San Antonio, Texas

Conditions: Healthy
Interventions: MK-8527, CBZ; Drug
Lead sponsor: Merck Sharp & Dohme LLC; Industry
Eligibility: 18 Years to 55 Years
Enrollment: 16 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2025
U.S. locations: 1
States / cities: Tempe, Arizona

Conditions: Hypertension, Pulmonary
Interventions: current marketed FLOLAN (epoprostenol sodium), new thermo stable formulation of epoprostenol sodium; Drug
Lead sponsor: GlaxoSmithKline; Industry
Eligibility: 18 Years to 75 Years
Enrollment: 16 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2011 – 2012
U.S. locations: 6
States / cities: Miami Beach, Florida • Chicago, Illinois • Baltimore, Maryland + 3 more

Conditions: Frontotemporal Dementia
Interventions: Part 1 Blinded - AL001, Part 1 Blinded - Placebo, Part 2 (OLE Treatment) - AL001, Part 2 (OLE Treatment) - Placebo Switched to AL001; Drug
Lead sponsor: Alector Inc.; Industry
Eligibility: 25 Years to 85 Years
Enrollment: 119 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2026
U.S. locations: 14
States / cities: Phoenix, Arizona • La Jolla, California • Aurora, Colorado + 11 more

Conditions: Acquired Immunodeficiency Syndrome, HIV Infections
Interventions: PI, RTV, FTC/TDF, Stribild; Drug
Lead sponsor: Gilead Sciences; Industry
Eligibility: 18 Years and older
Enrollment: 438 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2011 – 2014
U.S. locations: 45
States / cities: Phoenix, Arizona • Beverly Hills, California • Hayward, California + 28 more

Conditions: Contraception, Ovulation Inhibition, Contraceptives, Oral
Interventions: EE20/DRSP (BAY86-5300), EE20/DRSP (YAZ, BAY86-5300); Drug
Lead sponsor: Bayer; Industry
Eligibility: 18 Years to 45 Years · Female only
Enrollment: 1,887 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2007 – 2009
U.S. locations: 85
States / cities: Montgomery, Alabama • Chandler, Arizona • Mesa, Arizona + 74 more

Conditions: Multiple Sclerosis, Relapsing
Interventions: Ocrelizumab; Drug
Lead sponsor: Genentech, Inc.; Industry
Eligibility: 18 Years to 65 Years
Enrollment: 179 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2025
U.S. locations: 26
States / cities: Phoenix, Arizona • Los Angeles, California • Washington D.C., District of Columbia + 19 more

Conditions: Anemia, Renal Insufficiency, Chronic
Interventions: Molidustat (BAY85-3934), Epoetin alfa/beta; Drug · Biological
Lead sponsor: Bayer; Industry
Eligibility: 18 Years and older
Enrollment: 88 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2016
U.S. locations: 23
States / cities: Azusa, California • Long Beach, California • Lynwood, California + 16 more

Conditions: Primary Progressive Multiple Sclerosis, Secondary Progressive Multiple Sclerosis
Interventions: ATA188, Placebo; Biological · Drug
Lead sponsor: Atara Biotherapeutics; Industry
Eligibility: 18 Years to 60 Years
Enrollment: 134 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2024
U.S. locations: 25
States / cities: La Jolla, California • Los Angeles, California • Palo Alto, California + 22 more

Conditions: Lennox-Gastaut Syndrome (LGS)
Interventions: Placebo, Perampanel; Drug
Lead sponsor: Eisai Inc.; Industry
Eligibility: 2 Years and older
Enrollment: 101 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2021
U.S. locations: 31
States / cities: Little Rock, Arkansas • Palo Alto, California • Gulf Breeze, Florida + 25 more

Conditions: Schizophrenia
Interventions: PERSERIS, Risperidone; Drug
Lead sponsor: Indivior Inc.; Industry
Eligibility: 18 Years to 65 Years
Enrollment: 69 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2020
U.S. locations: 1
States / cities: Garden Grove, California

Conditions: Prurigo
Interventions: Ruxolitinib Cream, Vehicle Cream; Drug
Lead sponsor: Incyte Corporation; Industry
Eligibility: 18 Years to 99 Years
Enrollment: 204 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2025
U.S. locations: 18
States / cities: Phoenix, Arizona • Fort Smith, Arkansas • Fountain Valley, California + 15 more

Conditions: Diabetes Mellitus Type 2
Interventions: GK Activator (2), Metformin; Drug
Lead sponsor: Hoffmann-La Roche; Industry
Eligibility: 30 Years to 75 Years
Enrollment: 259 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2006 – 2007
U.S. locations: 22
States / cities: Chula Vista, California • Los Angeles, California • Spring Valley, California + 18 more

Search by objective public record fields.

Open-label Extension Study of AbobotulinumtoxinA (Dysport®) for the Treatment of Cervical Dystonia

Safety and Efficacy of E/C/F/TAF (Genvoya®) Versus E/C/F/TDF (Stribild®) in HIV-1 Infected, Antiretroviral Treatment-Naive Adults

A Multi-Center, Open Label, Extension Study Assessing the Efficacy and Safety of Additional Intravitreal Injections of RBM-007 in Subjects With Wet Age-related Macular Degeneration

A Study to Evaluate Safety, Tolerability, and Efficacy of Lecanemab in Subjects With Early Alzheimer's Disease

Open Label Extension of 2 mg/kg Pegunigalsidase Alfa (PRX-102) Every 4 Weeks in Adult Fabry Disease Patients

An Extension Study to Evaluate the Long-term Efficacy and Safety of Oxabact in Patients With Primary Hyperoxaluria

Extension Study of Maintenance Treatment With Subcutaneous Immunoglobulin (IgPro20) for Chronic Inflammatory Demyelinating Polyneuropathy (CIDP)

Long-Term, Open-label Study of Oral Deucrictibant Extended-Release Tablet for Prophylaxis Against Angioedema Attacks in Adolescents and Adults With HAE

Evaluate the Safety of Depakote Extended Release Tablets in the Treatment of Mania Associated With Bipolar Disorder in Children and Adolescents

Healthy Volunteers Study to Estimate the Effects of Food on the Bioavailability of Oxycodone and Naltrexone/6- Β -Naltrexol From a Extended Release Formulation of Oxycodone With Sequestered Naltrexone

Filgotinib in Long-Term Extension Study of Adults With Crohn's Disease

A Study to Demonstrate Bioequivalence Between Lorcaserin Extended Release (XR) Tablets Manufactured in Kawashima and Lorcaserin XR Tablets Manufactured in Zofingen in Healthy Participants

A Study of Carbamazepine (CBZ) and MK-8527 in Healthy Adult Participants (MK-8527-012)

Study of a New Thermo Stable Formulation of Epoprostenol Sodium to Treat Pulmonary Arterial Hypertension (PAH)

A Phase 3 Study to Evaluate Efficacy and Safety of AL001 in Frontotemporal Dementia (INFRONT-3)

Study to Evaluate Switching From Regimens Consisting of a Ritonavir-boosted Protease Inhibitor Plus Emtricitabine/Tenofovir Fixed-Dose Combination to the Elvitegravir/Cobicistat/Emtricitabine/Tenofovir DF Single-Tablet Regimen in Virologically Suppressed, HIV-1 Infected Patients

Efficacy and Safety of Two Flexible Extended Regimens of BAY86-5300 (SH T00186D) in Comparison With the Conventional Regimen of YAZ

Prospective Study to Assess Disease Activity and Biomarkers in Minority Participants With Relapsing Multiple Sclerosis (RMS) After Initiation and During Treatment With Ocrelizumab

Long Term Extension Study for the Maintenance Treatment of Anemia Associated With Chronic Kidney Disease (CKD) in Hemodialysis Subjects on Epoetin Alfa / Beta Treatment Versus BAY85-3934

Phase 1/2 Study to Evaluate the Safety and Efficacy of ATA188 in Subjects With Progressive Multiple Sclerosis

Study of Perampanel as Adjunctive Treatment for Inadequately Controlled Seizures Associated With Lennox-Gastaut Syndrome

Safety, Tolerability, Pharmacokinetics and Efficacy of 180 mg Subcutaneous Risperidone From 6 mg Oral Risperidone

A Study to Evaluate the Safety and Efficacy of Ruxolitinib Cream in Participants With Prurigo Nodularis (PN)

A Study to Evaluate the Long-Term Safety and Tolerability of GK Activator (2) in Patients With Type 2 Diabetes.